tradingkey.logo

Neuropace Inc

NPCE
13.120USD
+0.340+2.66%
終値 11/07, 16:00ET15分遅れの株価
436.65M時価総額
損失額直近12ヶ月PER

Neuropace Inc

13.120
+0.340+2.66%

詳細情報 Neuropace Inc 企業名

NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorder.

Neuropace Incの企業情報

企業コードNPCE
会社名Neuropace Inc
上場日Apr 22, 2021
最高経営責任者「CEO」Mr. Joel D. Becker
従業員数184
証券種類Ordinary Share
決算期末Apr 22
本社所在地455 N. Bernardo Avenue
都市MOUNTAIN VIEW
証券取引所NASDAQ Global Market Consolidated
United States of America
郵便番号94043
電話番号16502372700
ウェブサイトhttps://www.neuropace.com/
企業コードNPCE
上場日Apr 22, 2021
最高経営責任者「CEO」Mr. Joel D. Becker

Neuropace Incの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Frank M. Fischer
Mr. Frank M. Fischer
Independent Chairman of the Board
Independent Chairman of the Board
591.92K
+0.41%
Dr. Martha J. Morrell, M.D.
Dr. Martha J. Morrell, M.D.
Chief Medical Officer
Chief Medical Officer
69.64K
-1.88%
Mr. Patrick F. Williams
Mr. Patrick F. Williams
Chief Financial Officer
Chief Financial Officer
51.85K
--
Mr. Joseph S. (Joe) Lacob
Mr. Joseph S. (Joe) Lacob
Independent Director
Independent Director
38.48K
+3.03%
Ms. Rakhi Kumar, CPA
Ms. Rakhi Kumar, CPA
Independent Director
Independent Director
17.10K
+9.68%
Dr. Uri Geiger
Dr. Uri Geiger
Independent Director
Independent Director
13.23K
+9.92%
Mr. R. Scott (Scott) Huennekens
Mr. R. Scott (Scott) Huennekens
Independent Director
Independent Director
--
--
Ms. Renee Ryan
Ms. Renee Ryan
Independent Director
Independent Director
--
--
Mr. Joel D. Becker
Mr. Joel D. Becker
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Lisa Andrade
Ms. Lisa Andrade
Independent Director
Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Frank M. Fischer
Mr. Frank M. Fischer
Independent Chairman of the Board
Independent Chairman of the Board
591.92K
+0.41%
Dr. Martha J. Morrell, M.D.
Dr. Martha J. Morrell, M.D.
Chief Medical Officer
Chief Medical Officer
69.64K
-1.88%
Mr. Patrick F. Williams
Mr. Patrick F. Williams
Chief Financial Officer
Chief Financial Officer
51.85K
--
Mr. Joseph S. (Joe) Lacob
Mr. Joseph S. (Joe) Lacob
Independent Director
Independent Director
38.48K
+3.03%
Ms. Rakhi Kumar, CPA
Ms. Rakhi Kumar, CPA
Independent Director
Independent Director
17.10K
+9.68%
Dr. Uri Geiger
Dr. Uri Geiger
Independent Director
Independent Director
13.23K
+9.92%

収益内訳

FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q1
FY2023
FY2022
FY2021
FY2020
FY2019
データなし
地域別USD
会社名
収益
比率
United States
23.52M
0.00%
事業別
地域別
データなし

株主

更新時刻: Thu, Oct 9
更新時刻: Thu, Oct 9
株主統計
種類
株主統計
株主統計
比率
Accelmed Growth Partners Management Ltd
13.40%
Polar Capital LLP
9.36%
Soleus Capital Management, L.P.
8.94%
OrbiMed Advisors, LLC
7.90%
Morgan Stanley & Co. LLC
7.79%
他の
52.60%
株主統計
株主統計
比率
Accelmed Growth Partners Management Ltd
13.40%
Polar Capital LLP
9.36%
Soleus Capital Management, L.P.
8.94%
OrbiMed Advisors, LLC
7.90%
Morgan Stanley & Co. LLC
7.79%
他の
52.60%
種類
株主統計
比率
Investment Advisor/Hedge Fund
25.63%
Private Equity
21.30%
Hedge Fund
18.41%
Investment Advisor
17.73%
Research Firm
8.17%
Individual Investor
2.72%
Pension Fund
0.29%
Bank and Trust
0.07%
Insurance Company
0.03%
他の
5.65%

機関投資家保有株

更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
198
31.14M
94.13%
-2.95M
2025Q2
184
29.13M
88.81%
-1.17M
2025Q1
183
29.76M
92.98%
+2.27M
2024Q4
144
26.53M
86.07%
-49.99K
2024Q3
134
26.01M
86.62%
-1.02M
2024Q2
129
25.88M
90.53%
+502.69K
2024Q1
131
24.82M
87.55%
-513.24K
2023Q4
113
24.06M
92.70%
-1.70M
2023Q3
103
24.86M
97.20%
-1.10M
2023Q2
106
24.30M
96.22%
-2.15M
詳細を見る

株主動向

会社名
保有株式数
比率
変動額
変動率
日付
Accelmed Growth Partners Management Ltd
4.43M
13.4%
--
--
Apr 09, 2025
Soleus Capital Management, L.P.
2.31M
6.99%
-295.21K
-11.32%
Jun 30, 2025
OrbiMed Advisors, LLC
2.61M
7.9%
-792.15K
-23.26%
Jun 30, 2025
Morgan Stanley & Co. LLC
2.58M
7.79%
+52.63K
+2.08%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.54M
4.64%
+803.81K
+109.91%
Jun 30, 2025
The Vanguard Group, Inc.
1.37M
4.14%
+171.20K
+14.29%
Jun 30, 2025
First Light Asset Management, LLC
1.38M
4.17%
-203.64K
-12.86%
Jun 30, 2025
Armistice Capital LLC
1.15M
3.48%
-1.28K
-0.11%
Jun 30, 2025
Driehaus Capital Management, LLC
1.01M
3.04%
+201.92K
+25.13%
Jun 30, 2025
詳細を見る

関連ETF

更新時刻: Thu, Nov 6
更新時刻: Thu, Nov 6
銘柄名
比率
iShares Neuroscience and Healthcare ETF
0.43%
iShares Micro-Cap ETF
0.05%
Principal U.S. Small-Cap ETF
0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.03%
iShares Russell 2000 Growth ETF
0.02%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 ETF
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0.01%
Proshares Ultra Russell 2000
0.01%
詳細を見る
iShares Neuroscience and Healthcare ETF
比率0.43%
iShares Micro-Cap ETF
比率0.05%
Principal U.S. Small-Cap ETF
比率0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
比率0.03%
iShares Russell 2000 Growth ETF
比率0.02%
ProShares UltraPro Russell2000
比率0.01%
ProShares Hedge Replication ETF
比率0.01%
iShares Russell 2000 ETF
比率0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
比率0.01%
Proshares Ultra Russell 2000
比率0.01%

配当金

過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし

株式分割

日付
種類
比率
データなし
日付
種類
比率
データなし
KeyAI